1. Signaling Pathways
  2. GPCR/G Protein
    Immunology/Inflammation
  3. CXCR
  4. CXCR2 Isoform
  5. CXCR2 Antagonist

CXCR2 Antagonist

CXCR2 Antagonists (21):

Cat. No. Product Name Effect Purity
  • HY-16711
    SB225002
    Antagonist 99.87%
    SB225002, a potent, selective and non-peptide CXCR2 antagonist, inhibits 125I-IL-8 binding to CXCR2 with an IC50 of 22 nM.
  • HY-10198
    Navarixin
    Antagonist 99.13%
    Navarixin (SCH 527123) is a potent, allosteric and orally active antagonist of both CXCR1 and CXCR2, with Kd values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly.
  • HY-19855
    AZD-5069
    Antagonist 99.63%
    AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment.
  • HY-147392
    CXCR2 antagonist 8
    Antagonist
    CXCR2 antagonist 8 is a potent and selective CXCR2 antagonist.
  • HY-124056
    AZ10397767
    Antagonist
    AZ10397767 is an orally active, selective CXCR2 receptor antagonist with an IC50 of 1 nM.
  • HY-119259
    AZD8309
    Antagonist
    AZD8309 is an orally active antagonist of CXCR2.
  • HY-19768
    Danirixin
    Antagonist 98.45%
    Danirixin is a selective, and reversible CXCR2 antagonist, with IC50 of 12.5 nM for CXCL8.
  • HY-50688
    SB-265610
    Antagonist ≥99.0%
    SB-265610 is a selective, competitive, nonpeptide and allosteric CXCR2 antagonist.
  • HY-101407
    Nicotinamide N-oxide
    Antagonist 99.85%
    Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the CXCR2 receptor.
  • HY-120878
    CXCR2-IN-2
    Antagonist 98.45%
    CXCR2-IN-2 is a selective, brain penetrant, and orally bioavailable CXCR2 antagonist (IC50=5.2 nM/1 nM in β-arrestin assay/CXCR2 Tango assay, respectively).
  • HY-13021
    SRT3190
    Antagonist 99.32%
    SRT3190 is an antagonist of CXCR2, used in the research of chemokine mediated diseases.
  • HY-18263C
    Elubrixin tosylate
    Antagonist 99.74%
    Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist.
  • HY-19519A
    Ladarixin sodium
    Antagonist 99.15%
    Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist.
  • HY-10011
    SCH 563705
    Antagonist 98.20%
    SCH 563705 is a potent and orally available CXCR2 and CXCR1 antagonist, with IC50s of 1.3 nM, 7.3 nM and Kis of 1 and 3 nM, respectively.
  • HY-15462
    SRT3109
    Antagonist 99.82%
    SRT3109 is an antagonist of CXCR2, with a pIC50 of 8.2, and used in the research of chemokine mediated diseases.
  • HY-18263A
    Elubrixin
    Antagonist
    Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist.
  • HY-144784
    CXCR2 antagonist 7
    Antagonist
    CXCR2 antagonist 7 (compound 19) is a potent CXCR2 antagonist.
  • HY-144783
    CXCR2 antagonist 6
    Antagonist
    CXCR2 antagonist 6 (compound 35c) is a potent CXCR2 antagonist.
  • HY-144781
    CXCR2 antagonist 5
    Antagonist
    CXCR2 antagonist 5 (compound 25) is a potent CXCR2 antagonist.
  • HY-12927
    SX-517
    Antagonist
    SX-517 is a dual CXCR2/1 antagonist, containing boronic acid.